<PAGE>
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934
FILING NO. 1 FOR THE MONTH OF JUNE, 2000
VISIBLE GENETICS INC.
--------------------------
(Exact name of Registrant)
700 BAY STREET, SUITE 1000, TORONTO ON, CANADA M5G 1Z6
------------------------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F
Form 20-F X Form 40-F __
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
--------------------------------------------------------------------------------
<PAGE>
VISIBLE GENETICS INC.
On June 28, 2000 Visible Genetics Inc. issued a press release
reporting on the status of its FDA submission for its TRUGENE HIV-1
Genotyping Kit.
The press release is attached as Exhibit 1 to this Form 6-K and
incorporated into this Form 6-K by reference.
This Form 6-K contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks, uncertainties and
other factors which may cause our results to differ materially from
expectations. These include risks relating to the ability to obtain regulatory
approval, market acceptance of genotyping and our products and other risks
detailed from time to time in our SEC filings, including our most recent Annual
Report on Form 20-F. These forward-looking statements speak only as of the date
hereof. We disclaim any intent or obligation to update these forward-looking
statements.
We hereby incorporate by reference this Form 6-K into our Registration
Statements on Form F-3, and into the prospectuses contained therein, (File Nos.
333-67607, 333-68939, 333-91155 and 333-94649) and our outstanding Registration
Statements on Form S-8 and into the reoffer prospectuses contained therein.
Exhibit -- Press Release dated June 28, 2000
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VISIBLE GENETICS INC.
Date: June 28, 2000 By: /s/ RICHARD T. DALY
---------------------------
Name: Richard T. Daly
Title: President and CEO
